Diabetes

Die brasilianische Anvisa hat am Montag, dem 2. Februar 2026, die Erweiterung der therapeutischen Indikationen für Semaglutid, den Wirkstoff in Wegovy und Ozempic, genehmigt. Wegovy kann nun zur Reduzierung des Risikos von Herzinfarkten und Schlaganfällen bei Erwachsenen mit Herz-Kreislauf-Erkrankungen und Übergewicht eingesetzt werden, während Ozempic für Typ-2-Diabetes im Zusammenhang mit chronischer Nierenerkrankung indiziert ist. Die Behörde prüft auch einen Antrag auf eine orale Version von Wegovy.

2. Februar 2026 Von KI berichtet

Researchers at the University of Osaka have found that sustained high blood sugar levels raise the risk of tooth decay as sugars transfer from blood to saliva. In a survey of around 60 diabetic and nondiabetic individuals, higher blood sugar was linked to increased glucose and fructose in saliva, along with greater tooth decay and plaque.

Health care company Abbott has introduced Libre Assist, a new AI-powered tool within its Libre app, designed to help people with diabetes assess the potential impact of their meals on glucose levels before eating. Users can simply photograph or describe their food to receive predictions and tips. The feature, unveiled at CES 2026, integrates with Abbott's FreeStyle Libre continuous glucose monitors for post-meal insights.

4. Januar 2026 Von KI berichtet

Researchers at the University of Sydney have discovered that type 2 diabetes directly alters the heart's structure and energy production, increasing the risk of heart failure. By examining donated human heart tissue, the team identified molecular changes that stiffen the muscle and disrupt cellular function. These findings, published in EMBO Molecular Medicine, highlight a unique profile in patients with both diabetes and ischemic heart disease.

Researchers at Karolinska Institutet and Stockholm University have developed an experimental oral drug that boosts metabolism in skeletal muscle, improving blood sugar control and fat burning in early studies without reducing appetite or muscle mass. Unlike GLP-1-based drugs such as Ozempic, the candidate acts directly on muscle tissue and has shown good tolerability in an initial clinical trial, according to the study authors.

6. Dezember 2025 Von KI berichtet Fakten geprüft

A study in obese mice has found that the gut-derived hormone FGF19 can signal the brain to increase energy expenditure and activate fat-burning cells. Acting through the hypothalamus and the sympathetic nervous system, this mechanism enhances thermogenesis and cold tolerance and may help guide new treatments for obesity and diabetes.